ALK appoints Carsten Hellmann as new President and CEO
May 17 2016 - 12:38PM
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the
Board of Directors has appointed Carsten Hellmann as the new
President and CEO of the company.
Carsten Hellmann is currently CEO of Merial and Executive Vice
President and member of the Executive Committee of Sanofi
(NYSE:SNY). Headquartered in Lyon, Merial is Sanofi's Animal Health
company with annual sales of EUR 2.6 billion (DKK 19 billion) and
more than 7,000 employees worldwide. Before joining Sanofi, Carsten
Hellmann held executive positions in global health care and
biopharmaceutical companies including Chr. Hansen and Nunc Group.
Carsten Hellmann is a Danish citizen, born in 1964.
"It is a great pleasure to announce that Carsten Hellmann will
join ALK. Carsten Hellmann has extensive international experience
and a strong track record of creating visible commercial results in
research-based companies that share many similarities with ALK. We
are convinced that Carsten Hellmann has the competences required to
accelerate the global commercialisation of ALK's portfolio of
evidence-based products targeting both allergic rhinitis and
asthma," said Steen Riisgaard, Chairman of ALK's Board of
Directors.
Carsten Hellmann commented: "ALK stands out as the world leader
within allergy immunotherapy and the industry's foremost innovator.
I'm inspired by ALK's vision and excited to lead ALK through its
transformation to become a truly global company. ALK's innovative
product range and solid partnerships form a strong foundation for
growth, and I look forward to working with everyone at ALK to build
an even stronger future for our patients, employees, partners and
shareholders."
After a successful turn-around of Merial, Sanofi decided to
divest the company to Boehringer-Ingelheim and Carsten Hellmann
will complete this divestment before he takes up the position as
President and CEO of ALK which will happen no later than 1 January
2017. Steen Riisgaard will continue to take on extended operational
responsibilities until Carsten Hellmann is released from
Sanofi.
ALK-Abello A/S
For further information please contact:
Chairman of the Board of Directors and Acting CEO Steen Riisgaard,
tel. +45 4574 7576 Media: Jeppe Ilkjaer, tel. +45 7877 4532, mobile
+45 3050 2014
About Carsten Hellmann Carsten Hellmann holds a
BSc in Business Administration from Copenhagen Business School from
1989, an MSc from Lancaster University in Information Management
from 1990 and an executive programme from INSEAD. Carsten Hellmann
began his career in 1990 at Radiometer Medical A/S as a product
specialist before moving into a product manager role. He joined
Novo Nordisk in 1993 and held different roles in marketing,
business development, strategic alliances and business intelligence
with increasing responsibilities. In 1996, he joined Synthelabo as
Sales- and Marketing Director and in 1997 Pronosco A/S, a
diagnostics start up specialised in osteoporosis. In 2000 he was
named CEO at Nunc Group, a world leading life science consumable
company. After Fisher Scientific (now ThermoFisher) acquired Nunc
Group, Carsten Hellmann oversaw the integration processes before
joining Chr. Hansen Holding A/S in 2006 as Executive Vice
President, Global Sales, and member of the executive management
board. He was appointed to his present position as CEO of Merial (
www.merial.com ) and Executive Vice President of Sanofi
(www.sanofi.com) in 2013.
About ALK ALK is a research-driven global
pharmaceutical company focusing on allergy prevention, diagnosis
and treatment. ALK is a world leader in allergy immunotherapy - a
treatment of the underlying cause of allergy. The company has
approximately 2,000 employees, with subsidiaries, production
facilities and distributors worldwide. ALK has entered into
partnership agreements with MSD (known as Merck (NYSE:MRK) in the
USA and Canada) Torii, Abbott, and Seqirus to commercialise
sublingual allergy immunotherapy tablets in North America, Japan,
Russia, South-East Asia, Australia and New Zealand, respectively .
The company is headquartered in Hoersholm, Denmark, and listed on
NASDAQ Copenhagen. Find more information at www.alk.net .
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024